See more : Shenzhou International Group Holdings Limited (SZHIF) Income Statement Analysis – Financial Results
Complete financial analysis of Zelira Therapeutics Limited (ZLDAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zelira Therapeutics Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Indo Count Industries Limited (ICIL.BO) Income Statement Analysis – Financial Results
- Post Holdings, Inc. (POST) Income Statement Analysis – Financial Results
- Neo Infracon Limited (NEOINFRA.BO) Income Statement Analysis – Financial Results
- Founder Group Limited Ordinary Shares (FGL) Income Statement Analysis – Financial Results
- Buzzi Unicem S.p.A. (BZZUF) Income Statement Analysis – Financial Results
Zelira Therapeutics Limited (ZLDAF)
About Zelira Therapeutics Limited
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.95K | 301.12K | 1.54M | 663.32K | 0.00 | 769.03K | 313.76K | 100.04K | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.25K | 0.00 | 0.00 | 21.08M | 140.69K | 569.48K | 501.04K |
| Cost of Revenue | 84.67K | 3.52M | 939.05K | 228.22K | 275.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.85M | 70.66K | 178.19K | 141.29K |
| Gross Profit | 10.28K | -3.22M | 601.57K | 435.09K | -275.05K | 769.03K | 313.76K | 100.04K | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.25K | 0.00 | 0.00 | 24.93M | 70.03K | 391.29K | 359.75K |
| Gross Profit Ratio | 10.83% | -1,068.03% | 39.05% | 65.59% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 118.25% | 49.78% | 68.71% | 71.80% |
| Research & Development | 2.81M | 1.34M | 1.40M | 2.08M | 3.69M | 2.33M | 1.79M | 668.41K | 14.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.34M | 3.06M | 6.08M | 4.49M | 1.97M | 1.25M | 397.37K | 1.35M | 456.94K | 207.75K | 180.00K | 214.56K | 443.35K | 242.51K | 490.56K | 507.34K | 59.75K | 1.20M | 675.35K | 372.46K | 245.36K |
| Selling & Marketing | 0.00 | -468.36K | 715.24K | 510.07K | 0.00 | 0.00 | 0.00 | 1.05M | 63.25K | 83.84K | 67.65K | 84.80K | 123.57K | 126.28K | 490.52K | 365.25K | 187.33K | 333.39K | 62.53K | 46.07K | 60.51K |
| SG&A | 1.34M | 2.59M | 6.08M | 4.49M | 1.97M | 1.25M | 397.37K | 1.35M | 456.94K | 207.75K | 180.00K | 214.56K | 443.35K | 242.51K | 490.56K | 507.34K | 59.75K | 1.20M | 675.35K | 372.46K | 245.36K |
| Other Expenses | -4.14M | -266.52K | 1.28M | 1.25M | 925.49K | 580.44K | 959.82K | 99.34K | -24.95K | 12.16K | -15.78K | -18.92K | -36.03K | 440.67K | -201.19K | 177.42K | -211.08K | -1.51M | -99.53K | 45.46K | 522.50K |
| Operating Expenses | 10.28K | 4.20M | 14.25M | 10.20M | 7.94M | 4.24M | 2.83M | 6.32M | 876.42K | 423.83K | 295.18K | 322.06K | 630.63K | 463.08K | 1.15M | 1.85M | 487.99K | 46.55M | 1.35M | 860.64K | 1.04M |
| Cost & Expenses | 5.50M | 7.71M | 15.19M | 10.42M | 7.94M | 4.24M | 2.83M | 6.32M | 876.42K | 423.83K | 295.18K | 322.06K | 630.63K | 463.08K | 1.15M | 1.85M | 487.99K | 42.70M | 1.42M | 1.04M | 1.18M |
| Interest Income | 309.00 | 134.00 | 10.60K | 723.00 | 8.60K | 90.14K | 138.57K | 67.72K | 2.73K | 11.59K | 20.74K | 29.13K | 28.70K | 29.44K | 58.77K | 129.43K | 22.62K | 64.67K | 95.38K | 117.06K | 129.78K |
| Interest Expense | 739.27K | 76.66K | 53.85K | 42.63K | 12.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.25K | 0.00 | 102.20K | 203.13K | 4.83K | 16.00 |
| Depreciation & Amortization | 479.04K | 545.22K | 588.54K | 474.26K | 275.05K | 3.32M | 2.37M | 2.44M | 161.10K | 0.00 | 336.00 | 5.22K | 13.95K | 11.54K | 16.97K | 16.81K | 0.00 | 3.15M | 62.05K | 72.28K | 27.02K |
| EBITDA | -35.52M | -5.65M | -11.77M | -8.03M | -7.51M | 0.00 | 0.00 | 0.00 | 0.00 | -423.83K | -294.84K | -316.84K | -616.67K | -451.54K | -1.10M | -1.53M | -487.99K | -19.94M | -1.22M | -234.56K | 1.45K |
| EBITDA Ratio | -37,409.90% | -2,280.68% | -764.05% | -1,210.92% | 0.00% | -551.13% | -901.40% | -6,321.81% | -292.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,955.02% | 0.00% | 0.00% | -94.60% | -867.45% | -41.19% | 0.29% |
| Operating Income | -5.94M | -7.41M | -12.36M | -8.51M | -7.00M | -4.24M | -2.83M | -6.32M | -876.42K | -423.83K | -295.18K | -322.06K | -630.63K | -463.08K | -686.56K | -1.55M | -487.99K | -23.09M | -1.28M | -306.84K | -25.56K |
| Operating Income Ratio | -6,253.93% | -2,461.74% | -802.25% | -1,282.41% | 0.00% | -551.13% | -901.40% | -6,321.81% | -292.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,004.55% | 0.00% | 0.00% | -109.55% | -911.55% | -53.88% | -5.10% |
| Total Other Income/Expenses | -30.80M | 233.40K | -26.27K | 248.29K | 352.62K | -262.65K | 622.83K | -3.75M | -108.21K | 23.75K | 4.96K | 10.22K | -7.33K | 470.11K | -1.00M | -18.72M | 22.62K | -16.54M | -203.13K | -4.83K | 652.26K |
| Income Before Tax | -36.74M | -7.41M | -12.41M | -8.55M | -7.02M | -3.57M | -1.73M | -6.16M | -898.64K | -400.08K | -290.22K | -311.84K | -637.96K | 7.03K | -1.69M | -20.27M | -465.37K | -38.16M | -1.49M | -311.67K | -25.58K |
| Income Before Tax Ratio | -38,692.98% | -2,461.31% | -805.75% | -1,288.84% | 0.00% | -463.94% | -551.32% | -6,154.83% | -299.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,928.45% | 0.00% | 0.00% | -181.04% | -1,055.93% | -54.73% | -5.10% |
| Income Tax Expense | 0.00 | -1.14M | 860.83K | 1.30M | 937.84K | -769.03K | -313.76K | -100.04K | -163.83K | 0.00 | -20.74K | -29.13K | -28.70K | -29.44K | 370.74K | 211.67K | -13.08M | -1.41M | -584.27K | -311.67K | -25.58K |
| Net Income | -36.57M | -5.57M | -11.95M | -8.55M | -7.02M | -3.57M | -1.73M | -6.16M | -898.64K | -400.08K | -290.22K | -311.84K | -637.96K | 7.03K | -1.69M | -20.27M | 12.61M | -38.16M | -901.34K | -311.67K | 0.00 |
| Net Income Ratio | -38,513.04% | -1,850.75% | -775.35% | -1,288.84% | 0.00% | -463.94% | -551.32% | -6,154.83% | -299.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,928.45% | 0.00% | 0.00% | -181.04% | -640.65% | -54.73% | 0.00% |
| EPS | -3.22 | -0.55 | -1.49 | -1.29 | -1.45 | -0.83 | -0.40 | -2.18 | -1.39 | -0.73 | -0.53 | -0.57 | -1.99 | 0.02 | -5.03 | -116.56 | 464.49 | -15.47K | -543.30 | -255.26 | 0.00 |
| EPS Diluted | -3.22 | -0.55 | -1.49 | -1.29 | -1.45 | -0.83 | -0.40 | -2.18 | -1.39 | -0.73 | -0.53 | -0.57 | -1.99 | 0.02 | -5.03 | -116.56 | 464.49 | -15.47K | -543.30 | -240.67 | 0.00 |
| Weighted Avg Shares Out | 11.35M | 10.07M | 8.04M | 6.63M | 4.85M | 4.31M | 4.31M | 2.83M | 646.55K | 551.24K | 551.24K | 551.24K | 320.42K | 335.85K | 335.86K | 173.91K | 27.16K | 2.47K | 1.66K | 1.22K | 1.09K |
| Weighted Avg Shares Out (Dil) | 11.35M | 10.07M | 8.04M | 6.63M | 4.85M | 4.31M | 4.31M | 2.83M | 646.55K | 551.24K | 551.24K | 551.24K | 320.42K | 335.85K | 335.86K | 173.91K | 27.16K | 2.47K | 1.66K | 1.30K | 1.09K |
Zelira™ Launches RAF FIVE™ Acne Treatment Products Through Its Dermatology Focused Subsidiary
PHILADELPHIA, Sept. 23, 2021 /PRNewswire/ -- Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a global leader in the research and development of clinically validated cannabinoid medicines, is pleased to announce the US launch of the Zelira Dermatology Business' first product...
Zelira Therapeutics launches RAF FIVE™ CBD acne treatment products
Zelira Therapeutics Ltd, a leading global medicinal cannabis company, has launched its new line of CBD-based acne and skin products, RAF FIVE™. Developed in partnership with Harvard-trained and US board-certified cosmetic dermatologist Dr Karyn Grossman and noted drug development chemist...
Zelira Therapeutics expands into large German market via exclusive cannabis distribution agreement
Zelira Therapeutics Ltd has expanded into Europe via the large and growing German cannabinoid-based medicines market through an exclusive distribution agreement with Adjupharm GmbH, a German subsidiary of IM Cannabis Corp. The five-year agreement marks the first time ZLD has expanded...
Zelira Therapeutics' commercialisation program to see launch of suite of new cannabinoid-based products over FY22
Zelira Therapeutics Ltd continues to focus on the expansion of commercialisation activities and revenue generation from its new clinically tested products, with the strategy expected to lead to the launch of a suite of new cannabinoid-based products over FY22. Commercialisation...
Zelira Therapeutics closes out FY21 with record cash receipts ahead of product launches
Zelira Therapeutics Ltd has capped off the 2021 financial year with record cash receipts as it looks ahead to product launches later this year. The cannabinoid medicines developer finished the June quarter with A$311,000 in cash receipts — up 38%...
Zelira Therapeutics to go head-to-head with big pharma in US clinical pain trial
Zelira Therapeutics (ASX:ZLD) (OTCMKTS:ZALDF) has secured Institutional Review Board (IRB) approval for a pain observational trial to take place in the US. The cannabinoid medicines developer is set to test its patent-protected product against a big pharmaceutical company's multi-billion-dollar revenue...
Zelira Therapeutics has clinical trial results of Zenivol® published in SLEEP®
Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) (FRA:G1G) is encouraged that the results of a trial in chronic insomnia patients of its proprietary cannabinoid ZLT101 formulation marketed as Zenivol® have been published in the peer-reviewed journal SLEEP®. The double-blind, placebo-controlled, cross-over trial...
Zelira Therapeutics research demonstrates significant uptake of CBD into the brain
Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) (FRA:G1G) is buoyed that Curtin University researchers have developed a new technology that improves delivery of cannabidiol (CBD) based drugs into the brains of mice by up to 40-times. The research team, funded by Zelira, created tiny...
Zelira Therapeutics partners with Health House International to bring CBD toothpaste to the UK
Zelira Therapeutics Ltd's (ASX:ZLD) (OTCMKTS:ZLDAF) (FRA:G1G) CBD-formulated toothpaste is primed to hit the UK market under an exclusive distribution agreement. The healthcare company inked the distribution deal with fellow ASX-lister Health House International Ltd (ASX:HHI), which teamed up with Zelira...
Zelira Therapeutics teams up with Levin Health to trial cannabinoid treatment for chronic pain in retired athletes
Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) has licensed its cannabis formulation to Levin Health Limited for an upcoming clinical trial. Levins will use the medicinal cannabis company's ZTL-106 formulation for testing on retired athletes in a chronic pain treatment study at La Trobe...
Source: https://incomestatements.info
Category: Stock Reports